Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 1
2006 1
2007 1
2008 3
2009 3
2010 6
2011 5
2012 4
2013 4
2015 1
2016 1
2017 2
2018 3
2019 2
2020 4
2021 7
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Sanchorawala V, Palladini G, Minnema MC, Jaccard A, Lee HC, Gibbs S, Mollee P, Venner C, Lu J, Schönland S, Gatt M, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Chauveau D, Gries KS, Fastenau J, Tran NP, Qin X, Vasey SY, Weiss BM, Vermeulen J, Ho KF, Merlini G, Comenzo RL, Kastritis E, Wechalekar AD. Sanchorawala V, et al. Among authors: cibeira mt. Am J Hematol. 2022 Jun 1;97(6):719-730. doi: 10.1002/ajh.26536. Epub 2022 Mar 30. Am J Hematol. 2022. PMID: 35293006 Free article. Clinical Trial.
Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis.
Muchtar E, Dispenzieri A, Wisniowski B, Palladini G, Milani P, Merlini G, Schönland S, Veelken K, Hegenbart U, Geyer SM, Kumar SK, Kastritis E, Dimopoulos MA, Liedtke M, Witteles R, Sanchorawala V, Szalat R, Landau H, Petrlik E, Lentzsch S, Coltoff A, Bladé J, Cibeira MT, Cohen O, Foard D, Wechalekar A, Gertz MA. Muchtar E, et al. Among authors: cibeira mt. J Clin Oncol. 2023 Mar 1;41(7):1393-1403. doi: 10.1200/JCO.22.00643. Epub 2022 Oct 10. J Clin Oncol. 2023. PMID: 36215675 Free PMC article.
Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis.
Kastritis E, Leleu X, Arnulf B, Zamagni E, Cibeira MT, Kwok F, Mollee P, Hájek R, Moreau P, Jaccard A, Schönland SO, Filshie R, Nicolas-Virelizier E, Augustson B, Mateos MV, Wechalekar A, Hachulla E, Milani P, Dimopoulos MA, Fermand JP, Foli A, Gavriatopoulou M, Klersy C, Palumbo A, Sonneveld P, Johnsen HE, Merlini G, Palladini G. Kastritis E, et al. Among authors: cibeira mt. J Clin Oncol. 2020 Oct 1;38(28):3252-3260. doi: 10.1200/JCO.20.01285. Epub 2020 Jul 30. J Clin Oncol. 2020. PMID: 32730181 Clinical Trial.
Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.
Moreno DF, López-Guerra M, Paz S, Oliver-Caldés A, Mena MP, Correa JG, Battram AM, Osuna M, Rivas-Delgado A, Rodríguez-Lobato LG, Cardús O, Tovar N, Cibeira MT, Jiménez-Segura R, Bladé J, Rosiñol L, Colomer D, Fernández de Larrea C. Moreno DF, et al. Among authors: cibeira mt. Br J Haematol. 2023 Jan;200(2):187-196. doi: 10.1111/bjh.18502. Epub 2022 Oct 9. Br J Haematol. 2023. PMID: 36210485 Free PMC article.
Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal Gammopathy.
Moreno DF, Pereira A, Tovar N, Cibeira MT, Magnano L, Rozman M, López-Guerra M, Colomer D, Martín-Antonio B, Jiménez-Segura R, Isola I, Rodríguez-Lobato LG, Oliver-Caldés A, Mena MP, Rosiñol L, Bladé J, Fernández de Larrea C. Moreno DF, et al. Among authors: cibeira mt. Cancers (Basel). 2021 Apr 23;13(9):2055. doi: 10.3390/cancers13092055. Cancers (Basel). 2021. PMID: 33922804 Free PMC article.
50 results